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ABSTRACT
Background/objective: To describe the design of ‘DepMod,’ a health-economic Markov model for 
assessing cost-effectiveness and budget impact of user-defined preventive interventions and treat-
ments in depressive disorders.
Methods: DepMod has an epidemiological layer describing how a cohort of people can transition 
between health states (sub-threshold depression, first episode of mild, moderate or severe depression 
(partial) remission, recurrence, death). Superimposed on the epidemiological layer, DepMod has an 
intervention layer consisting of a reference scenario and alternative scenario comparing the effective-
ness and cost-effectiveness of a user-defined package of preventive interventions and psychological 
and pharmacological treatments of depression. Results are presented in terms of quality-adjusted life 
years (QALYs) gained and healthcare expenditure. Costs and effects can be modeled over 5 years and 
are subjected to probabilistic sensitivity analysis.
Results: DepMod was used to assess the cost-effectiveness of scaling up preventive interventions for 
treating people with subclinical depression, which showed that there is an 82% probability that scaling 
up prevention is cost-effective given a willingness-to-pay threshold of €20,000 per QALY.
Conclusion: DepMod is a Markov model that assesses the cost-utility and budget impact of different 
healthcare packages aimed at preventing and treating depression and is freely available for academic 
purposes upon request at the authors.
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Depressive disorder has consistently been highlighted as 
a leading cause of disease burden, particularly in terms of 
years lived with disability (YLD) [1–6]. Depression is associated 
with substantial economic costs from a patient perspective, 
a healthcare perspective and a societal perspective [7,8]. For 
example, the total annual cost of depression in Europe was 
estimated at €118 billion in 2004 [8].
Extensive research has been done on the effectiveness of 
both the treatment of depression (e.g. [9–13]), and the pre-
vention of depression [14,15]. Optimizing a healthcare system 
under restricted budgets requires that the cost-effectiveness 
of a package of interventions can be assessed along with 
associated impacts of implementing an intervention on the 
healthcare budget. Such information helps to inform policy-
makers about the implications of reforming the healthcare 
system. One way of addressing these issues is to develop 
a health-economic model which synthesizes all available evi-
dence, while also considering preferences of patients and 
healthcare professionals.
The aim of this paper is to present a health-economic 
simulation model for depression, DepMod, and to describe 
DepMod’s design features and how it can be put to use to 
inform policymakers about the health and cost implications of 
changing the healthcare system for depressive disorders. 
DepMod builds on previous health-economic models, such 
as the ACE (Assessing Cost Effectiveness) prevention models 
[16], and CHOICE (CHOosing Interventions that are Cost- 
Effective) models [17]. To promote transparency regarding 
the model structure (its inputs, assumptions, strengths and 
limitations), this paper presents the building blocks of the 
model to enable future users of the model to use it for 
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answering their own research questions and adapt the model 
to their own (geographical) context in terms of epidemiology 
and treatment mix for the prevention and treatment of major 
depressive disorder.
2. Methods
2.1. Problem definition and target population
The aim of the model is to compare the cost-effectiveness and 
budget impact of competing intervention packages targeting 
adults with, or at risk of developing, a depressive disorder in 
the Netherlands, such that the model contributes to optimiz-
ing health outcomes under budget constraints.
2.2. Model development
DepMod was developed as a decision-analytic and health- 
economic Markov model built-in Microsoft Excel. Such 
a model evaluates costs and health outcomes by simulating 
a cohort of hypothetical patients that transition across a series 
of health and disease states (healthy, at risk, depressed, relap-
sing, chronic (partially) recovered, death) until the end of the 
model’s time horizon. The outcomes of the model (costs and 
quality-adjusted life years gained) are then synthesized into 
incremental cost-effectiveness ratios [18].
The development of the health-economic model DepMod 
was in line with the recommendations from the International 
Society for Pharmacoeconomics and Outcomes Research [19], 
starting off with scoping the types of research questions that 
DepMod should be able to answer, conceptualizing the 
model, gathering evidence from relevant sources, and testing 
the model with the model users and stakeholders. Figure 1 
depicts the schematic overview of the development of the 
model.
Expert input was used throughout the process of develop-
ing the health-economic model. In drafting the starting point 
of the conceptual model, researchers in the field of depression 
were consulted.
The model was then refined in an iterative process where 
the model was updated multiple times based on feedback by 
healthcare users, healthcare professionals, and researchers 
involved in the development of a Standard of Care for treating 
depressive disorders in the Netherlands [20].
During the iterative updating process, DepMod’s scope was 
defined in terms of the following PICOT:
● Population: Dutch adults (aged 18–65 years) with sub- 
threshold, mild, moderate, and severe major depression 
as defined by DSM-IV with the possibility of recurrences, 
which is in line with the major source of available epi-
demiological evidence (i.e. The Netherlands Mental 
Health Survey and Incidence Study-1 (NEMESIS-1), and 
NEMESIS-2 [21–23]).
● Intervention: User-defined intervention(s) which will be 
compared to a reference scenario. The intervention in 
DepMod can either be a single intervention or a mix of 
interventions (e.g., scaling up existing evidence-based 
interventions or adding new preventive interventions).
● Comparator: User-defined reference scenario, typically 
the treatments provided under care as usual, to which 
the intervention will be compared.
● Outcome: Additional healthcare expenditure (in €) rela-
tive to quality-adjusted life years (QALYs) gained.
● Time horizon: Costs and QALYs can be modeled out over 
5 years (as there is a paucity of evidence in the literature 
on longer-term health effects induced by treatments).
Figure 1. Schematic overview of the model development process.
Article highlights 
● DepMod is a methodologically sound model that can be used to 
examine the cost-effectiveness and budget impact of a user-defined 
package of preventive interventions and psychological and pharmaco-
logical treatments of depression
● DepMod can be used for various interventions (e.g., medication, 
cognitive behavior therapy, et cetera) in a relatively easy and acces-
sible way.
● The transition rates between health states were derived from 
NEMESIS-2, a large psychiatric cohort study of adults (18 – 65 
years) in the Netherlands, but DepMod permits user-defined adaption 
of its epidemiology for use in other geographies or age groups.
● For illustrative purposes, DepMod was used to assess the cost- 
effectiveness of scaling up preventive interventions for treating peo-
ple with subclinical depression in the Netherlands, which showed 
that there is an 82% probability that scaling up prevention is cost- 
effective given a willingness-to-pay threshold of €20,000 per QALY.
● DepMod is freely available for academic purposes upon request by 
the authors.
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In addition, the following a priori design criteria for the model 
were adopted:
● Taking a Markov model approach similar to ACE [16] and 
CHOICE [17]. A Markov model was preferred over 
a micro-simulation (or discrete event) approach, as our 
aim was to make a population-level model, which makes 
individual traits affecting the course of illness less 
relevant.
● Taking a healthcare system approach, looking at 
packages of interventions (instead of individual interven-
tions) to be compared to a ‘reference scenario’ (e.g., 
depression care concordant with the latest clinical guide-
line) with an ‘alternative scenario’ (e.g., an alternative 
user-defined package of interventions for depression).
● Using an incidence-based model (e.g., of the depressive 
disorder in the Dutch adult population), to be able to 
examine the impact of preventive interventions.
2.3. A layered model structure
DepMod is a layered model. In the first layer, the epidemiol-
ogy of depression in the Dutch population is simulated (inci-
dence, disease duration, remission, recurrence, chronicity, and 
depression-related excess mortality). A second layer is super-
imposed on the epidemiological substratum. Here a set of 
interventions can be modeled along with their coverage and 
compliance rates, their effectiveness and the costs of offering 
the interventions. Both layers are described in more detail 
below.
2.3.1. Epidemiological layer
To apply DepMod to the Dutch situation, NEMESIS-1 and 
NEMESIS-2 [21–23], both Dutch population-based cohort stu-
dies on the incidence and prevalence of mental disorders, 
served as the main sources to build DepMod’s epidemiological 
substratum. NEMESIS-2 was used to obtain the most recent 
available data on the incidence and prevalence of depression. 
Furthermore, experts provided literature on chronicity [24] 
(partial) recovery/duration [25], and recurrence of depression 
[26]. These were modeled as transition rates between the 
health and disease states In DepMod. The model takes 
a population-incidence approach, where available evidence 
on the incidence of depression was used as direct input to 
the model, and transition parameters such as remission and 
recurrence rates were calibrated such that resulting preva-
lence-based outcomes matched the prevalence-based out-
comes reported in NEMESIS-2.
2.3.2. Intervention layer
Superimposed on the epidemiological layer, DepMod has an 
intervention layer consisting of a reference scenario and an 
alternative scenario to compare the effectiveness and cost- 
effectiveness of a user-defined package of preventive inter-
ventions and psychological and pharmacological treatments 
of depression. Each intervention is described by four para-
meters: effectiveness (standardized mean difference in case 
of treatment, and risk difference or relative risk in case of 
prevention), per-patient intervention costs (in €), coverage 
(the fraction of the target population receiving the interven-
tion) and adherence (the fraction of users compliant with that 
intervention).
End-users can modify the included interventions in 
DepMod according to their own preference. The effectiveness 
parameters for interventions are best extracted from the meta- 
analytical trial literature, while coverage and adherence rates 
can be elicited from focus groups of clinicians and patients, 
respectively.
2.3.3. Conceptual model
Figure 2 depicts the conceptual model formed by depression 
experts that was used as a starting point in developing the 
model. The conceptual model begins with the population at- 
risk of developing a depression (e.g., the estimated 456,600 
people with subthreshold depression (warranting indicated 
prevention) in the Dutch adult population), which can develop 
into a mild, moderate or severe major depressive disorder. 
Depression can then either remit (fully or partially) or not, 
and -in case of (partial) remission-transit into a recurrent 
major depressive disorder or remain a single episode. People 
developing a second episode of depression reenter the loop, 
where they can again remit and develop a next episode of 
depression.
2.4. Perspective, outcomes and time horizon
DepMod takes a healthcare perspective, considering the costs 
and effects of interventions for preventing first episodes of 
depression, treatment of acute depressive episodes, and pre-
vention of recurrent episodes of depression. Health outcomes 
are expressed as QALYs. QALYs are based on the health state 
valuations for mild, moderate, and severe depressive disorder 
of 0.86, 0.65, and 0.24, respectively, as reported by Stouthard 
et al. [27], whereas changes in health-related quality of life are 
based on the standardized effect sizes of the interventions 
that are converted to utilities using Sanderson et al.’s (2004) 
conversion factor [28]. Total QALYs are estimated by multi-
plying the time spend in a specific health state by the valua-
tion (utility) of that health state [18]. The model uses a time 
horizon of 5 years to capture the longer-term health effects of 
treatment and prevention of depression without extrapolating 
too far from the available evidence-base. Costs and QALYs 
occurring after 1 year are discounted at 4% and 1.5%, respec-
tively, to account for differential timing, in accordance with 
the Dutch guideline for health economic evaluation [29].
In DepMod, the incremental cost-effectiveness ratio for the 
alternative scenario as compared to the reference scenario, is 
calculated by dividing the difference in total healthcare costs 
(between the alternative and reference scenario) by the differ-
ence in effects between the scenarios. Probabilistic sensitivity 
analyses are conducted by calculating the costs and effects in 
the reference scenario and alternative scenario by a user- 
defined number of times (e.g., 1,000 times) using Monte 
Carlo simulation, where each time a parameter value for 
each of the parameters is drawn at random from underlying 
cost, effect, and transition distributions. We assume costs to 
be Gamma distributed, standardized effect sizes to be 
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normally distributed, and transition probabilities to follow 
a beta-distribution, in line with recommendations [18]. 
Results of probabilistic sensitivity analyses are depicted in 
a cost-effectiveness plane and a cost-effectiveness acceptabil-
ity curve, presenting the probability that the alternative 
healthcare scenario is cost-effective compared to the reference 
scenario, given varying levels of willingness-to-pay for a QALY 
gained [30].
2.5. Epidemiology and the Markov model
Available evidence on epidemiology determined to which 
extent the level of detail as depicted in the conceptual model 
in Figure 2 could be modeled. As available evidence reported 
mostly in time intervals of 1 year, it was chosen to use a cycle 
length in our Markov-model of 1 year as well. A half-cycle 
correction was applied to account for the fact that transitions 
between states are expected to occur on average in the middle 
of each cycle [31]. It was chosen to only model the states 
‘subthreshold depression’ (without a history of depression), 
‘depressive episode’ (first or recurrent episode), ‘no depression,’ 
a ‘chronic state’ (i.e., more than 2 years), ‘cured’ (absence of 
(subthreshold) depression, and ‘death.’ In line with Solomon 
et al. (2000), up to five depressive episodes were considered, 
which resulted in the Markov-model as depicted in Figure 3 [32]. 
Technically, to allow for increasing recurrence rates after each 
previous episode (i.e., to build memory into the Markov-model), 
we constructed a transition matrix containing tunnel states [33] 
for the number of depressive episodes (at most five, i.e., one 
per year), representing the transition rates after no previous 
episode, one previous episode, etc.
Based on NEMESIS-2, the first (one-year) incidence rate was 
set at 1.28% [23]. Transition parameters that could not be 
taken from literature were calibrated (see Table 1) such that 
the resulting epidemiology matched the internally consistent 
epidemiological structure of depression as derived from the 
NEMESIS-studies (see Figure 4). Recurrence rates were based 
on Solomon et al. (2000), who reported that the risk of recur-
rence increases with on average 16% after each previous 
episode of major depression. In our model, recurrence rates 
ranged from a 21% risk of recurrence within 12 months given 
one previous episode, to an 88% risk of recurrence within 5 
years given four previous episodes [32]. Solomon et al. (2000) 
report 13 recurrence rates (for differing number of previous 
episodes and number of years until recurrence), along with 
their confidence intervals. DepMod defines 25 distinct recur-
rence rates (one to five recurrences that can each occur 1 to 5 
years after the previous episode), which was simplified by 
estimating the average relative increase in recurrence rates 
after the first up to the fifth episode (so five increased recur-
rence rates) and five probabilities regarding the number of 
years after which the recurrence occurs. To allow for increas-
ing recurrence rates, each of the depressive episodes (first to 
the fifth) was modeled as separate Markov tunnel states.
In line with NEMESIS-2, reporting a prevalence of major 
depression of 5.2% [34], the epidemiology as modeled by 
DepMod resulted in a 12-month prevalence rate of 5.18%. 
Chisholm et al. (2004) reported the proportion of people 
with a mild, moderate, and severe depression as 30%, 47%, 
Figure 2. Conceptual model of the course of depression serving as a starting point in the process of model development.
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and 23%, respectively [35]. The epidemiology in DepMod was 
calibrated to match this distribution (see Table 1).
Background mortality was based on (weighted) average 
mortality rate of adults between 18 and 65 in the 
Netherlands [36]. Depression-related excess mortality (e.g., 
due to unhealthy behavior or suicide) was calibrated to be in 
line with NEMESIS-2, resulting in a relative risk of 1.65.
An economic evaluation compares the costs and effects of 
two alternatives. In DepMod, the reference scenario can be 
compared to an alternative scenario, simply by copying in this 
reference scenario and adjusting some of its parameters. For 
example, increasing the coverage rate of prevention implies 
that more prevention is offered in the alternative scenario, 
which may then cascade into a range of health and economic 
impacts (see, e.g. [37]).
2.6. Effectiveness of interventions
The effectiveness of interventions impacts positively on the 
epidemiology in three different ways:
● through a reduction in the transition from the at-risk 
status to a first episode of depression (primary preven-
tion) and a reduction in the transition to a recurrent 
depression (prevention of recurrence). The effectiveness 
of prevention is expressed as either a risk difference 
(primary prevention) or a relative risk (prevention of 
recurrence).
● through symptom improvement in people currently suf-
fering from mild, moderate or severe depression. 
Symptom improvement follows from standardized effect 
sizes (Cohen’s d; i.e. standardized mean difference), 
expressing improvement on a depression-related symp-
tom scale in standard units, and should be based on 
meta-analyses where possible. The average symptom 
improvement can be downward adjusted for less than 
optimal coverage and impaired adherence (by multipli-
cation with the coverage and adherence rates). The 
resulting adjusted effect sizes are then converted into 
QALYs using Sanderon et al.’s (2004) conversion factor 
[28] and assuming that treatment effects would last as 
long as (but not longer than) the average episode dura-
tion of depression.
● through a prophylactic effect, where receiving psycholo-
gical intervention for the treatment of a depressive epi-
sode may increase the likelihood of staying in remission 
after successful treatment (rather than recurrence at end 
of treatment), because psychological intervention (unlike 
pharmaceutical intervention) is suggested to train 
patients to better self-manage emerging depressive 
symptoms should these re-occur in the future.
The total QALY gain is then determined by difference in total 
QALYs between the reference and alternative scenarios.
3. Results of model testing
To apply DepMod to a real-world example, a list of evidence- 
based interventions needs to be constructed. In our applica-
tion, we constructed a reference scenario by using a list of 
Figure 3. Markov-model.
Arrows representing all possible transitions from one state to another. In the model, each arrow is represented by a transition probability. 
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evidence-based interventions, using the Dutch multidisciplin-
ary guideline for depression (see Table 2) [20]. This healthcare 
system served as a reference scenario against which alterna-
tive intervention mixes (i.e., alternative scenarios) could be 
compared in terms of cost-effectiveness and budget impact. 
The effectiveness of included interventions was based on 
meta-analyses (see Table 2).
With the interventions in the reference scenario defined, it 
is possible to conduct what-if analyses, where the user can 
assess the cost-effectiveness of hypothetical alternative 
healthcare systems. For example, currently, first-incidence pre-
vention and prevention of depression is not systematically 
offered in the Netherlands although it has been recom-
mended in clinical guidelines for some time. For illustrative 
purposes, we’ve assessed the cost-effectiveness of scaling up 
preventive interventions for people with subclinical depres-
sion (i.e., online CBT) and people at risk of developing 
a recurrent depression with a coverage of 15%. Hence, we 
simply copied the reference scenario as outlined in Table 2 
into the alternative scenario and increased the coverage rates 
of the preventive interventions from 0% to 15%.
In this example, intervention costs were estimated by mul-
tiplying the guideline concordant resource use associated with 
each intervention by their standard (unit) cost price, as listed 
in the Dutch guideline for health-economic evaluation [29]. 
Costs were expressed in 2019 Euros. The resulting costs per 
intervention are shown in Table 3.
Increasing the coverage rate of prevention from 0% to 15% 
and subsequently simulating the costs and effects of both 
healthcare systems, results in the cost-effectiveness plane 
and cost-effectiveness acceptability curve depicted in Figure 
5. The output tells us that at the commonly accepted will-
ingness-to-pay threshold of €20,000 per QALY, there is an 82% 
probability that scaling up prevention is cost-effective.
Furthermore, the expected 18,400 QALYs gained by offer-
ing the additional prevention over the considered time hor-
izon of 5 years require an additional budget of €191.1 million 
euros (net present value). Tabulated results can be found in 
Appendix 1.
4. Discussion
We built a Markov model to evaluate the cost-effectiveness 
and budget impact of a healthcare system of psychological 
and pharmacological interventions for people with depressive 
disorders, as well as people at risk of developing a first or 
Table 1. Parameters in DepMod (point estimates, range, justification).
Input parameters Point estimate Sensitivity Source
Incidence 1.28% NA De Graaf et al., 2013[23]
Disability weights depression 
Mild (dw) 0.14 0.086 - 0.194 Stouthard et al., 1997[27]
Moderate (dw) 0.35 0.272 – 0.425 Stouthard et al., 1997[27]
Severe (dw) 0.76 0.556 – 0.971 Stouthard et al., 1997[27]
Depression duration
Mild 3 months NA based on Spijker et al., 2002[24]
Moderate 6 months NA based on Spijker et al., 2002[24]
Severe 9 months NA based on Spijker et al., 2002[24]
Background mortality 0.001984 NA Based on life tables [36]
Calibration parameters Point estimate Sensitivity To match outcome
severity distribution at incidence
Mild 30.0% NA distribution prevalence mild, 
moderate, severe depression as 





after 1st episode 59.8% NA recurrence rates as reported in 
Solomon et al., 2000[32]after 2nd episode 77.2% NA
after 3rd episode 84.2% NA
after 4th episode 91.1% NA
after 5th episode 92.9% NA
Occurring after
one year 40% NA recurrence rates as reported in 
Solomon et al., 2000[32]two years 30% NA
three years 20% NA
four years 7% NA
five years 3% NA
Excess mortality  1.65 NA De Graaf et al., 2012[34]
Outcomes Model outcome Reference value Source
Prevalence of depression 5.24% 5.21% De Graaf et al., 2012[34]
Severity distribution
Mild 30.4% 30% Chisholm et al., 2004[35]
Moderate 47.0% 47% Chisholm et al., 2004[35]
Severe 22.7% 23% Chisholm et al., 2004[35]
Recurrence rates ranging from 24% (risk of recurrence 
after 1 year, given 1 previous 
episode) to 84% (risk of recurrence 
after 5 years given 4 previous 
episodes)
ranging from 25% (20%-32%) (risk of 
recurrence after 1 year, given 1 
previous episode) to 79% (35%-95%) 
(risk of recurrence after 5 years given 
3 previous episodes)
Solomon et al., 2000[32]
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recurrent episode of depression. Taking the healthcare system 
perspective, the model combines available evidence on the 
epidemiology of depressive disorder, the effectiveness of 
interventions, and the costs of the interventions while con-
sidering the preferences of healthcare professionals and 
healthcare users for offering and receiving interventions. The 
Figure 4. Internally consistent epidemiological structure of depression based on NEMESIS-studies (yearly number of people in each health state in parentheses).
Table 3. Intervention costs expressed in 2019 Euros.
Intervention by depression severity level
Prevention of first incidence (targeting 
subclinical depression)
€* Resource use
E-health intervention (unsupported) 160 1x GP; intake psychologist; 4–9 sessions unsupported online self-help; incl. hosting costs
Treatment of mild depression € Resource use
E-health intervention (supported) 265 1x GP; intake psychologist; 4–9 sessions online self-help; 4–5 telephone support prevention worker; hosting 
cost of the e-health intervention
Individual psychotherapy 962 1x GP; 8 sessions with a psychologist; coordination with GP
Treatment of moderate depression € Resource use
E-health intervention (supported) 265 1x GP; intake psychologist; 4–9 sessions online self-help; 4–6 telephone support prevention worker; hosting
Individual psychotherapy 962 1x GP; 8 sessions with a psychotherapist; coordination with GP
Treatment of severe depression € Resource use
Individual psychotherapy, outpatient care 1,984 1x GP; 8–24 sessions by a psychotherapist
Antidepressants 607 12 months of medication; contacts with GP or psychiatrist
Antidepressants with additional psychological 
support
679 12 months of medication; contacts with GP or psychiatrist; 3–6 visits GP support
Combination therapy (medication plus 
psychotherapy)
2,520 12 months of medication; contacts with GP or psychiatrist; 8–24 sessions with a psychotherapist
Prevention of recurrent depression € Resource use
Clinical management with maintenance 
medication
1,002 1x psychiatrist; 8–14 visits GP; 12 months of medication
Mindfulness-based CT 361 1x GP; 8 group sessions (11 participants on average)
Cognitive (behavior) therapy 429 1x GP; 8 group sessions (8 participants on average)
* Intervention costs were estimated by multiplying the guideline concordant resource use associated with each intervention by their standard (unit) cost price, as 
listed in the Dutch guideline for health-economic evaluation. 
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model was refined using feedback by healthcare users, health-
care professionals, and researchers in the field of depression. 
DepMod adds to other health-economic models described in 
literature (e.g. [42–45]) by (i) considering both the prevention 
and treatment of depression, (ii) considering both psychologi-
cal and pharmacological interventions, (iii) modeling increas-
ing recurrence rates for patients with a higher number of 
previous episodes, (iv) considering a five-year time horizon, 
and (v) allowing for assessing the cost-effectiveness of inter-
ventions aiming to increase adherence. The model can be 
adapted to other settings by adding or removing interven-
tions, by altering their coverage rate, adherence rate, or 
healthcare costs and by adjusting the epidemiology.
Outcomes of the model were shown in an example for the 
Dutch situation where the cost-effectiveness and budget 
impact were assessed of increasing the coverage of preventive 
interventions. Results of that analysis showed favorable out-
comes suggesting that, when assuming a willingness-to-pay 
threshold of €20,000 per QALY, scaling up prevention is likely 
to be cost-effective. This finding is in line with previous 
research in this field that demonstrated that depression pre-
vention is associated with probabilities in the range of 68–90% 
of being cost-effective [46–49]. This example demonstrates the 
ability of the model to assess the cost-effectiveness of alter-
native healthcare systems, while making use of an extensive 
evidence-base from epidemiology, clinical effectiveness and 
economic costs.
4.1. Strengths and limitations
The strength of our model is that it synthesizes information 
from different domains into a single model that can be used 
by policymakers as a decision-support tool for estimating the 
cost-effectiveness and budget impact of alternative interven-
tion packages by incorporating fully tweakable scenarios. 
However, our model has a number of limitations that need 
to be acknowledged.
First of all, because information from different domains was 
combined, it was necessary to make assumptions, for example, 
on how effectiveness of interventions impacted on epidemiol-
ogy, thereby introducing uncertainty in the model’s outcomes. 
Whenever assumptions had to be made, we favored conser-
vative assumptions that are more likely to underestimate the 
cost-effectiveness of interventions.
A second limitation of DepMod, common in health- 
economic models, is the presence of uncertainty regarding 
both input parameters like transition probabilities (parameter 
uncertainty) and structural model choices like the chosen 
health states or type of analytical framework (model uncer-
tainty). Parameter uncertainty was addressed using probabil-
istic sensitivity analysis on the parameters of interest. 
Although we partially account for model uncertainty, the 
main value of our model lies in interpreting the comparison 
between the outcomes of two scenarios, rather than the 
absolute costs and effects associated with a single scenario.
A third limitation is that there is no unique solution when 
determining each of the calibration parameters of the Markov 
model. Given the episodic nature of depressive disorder, the 
epidemiology cannot be modeled using just incidence, pre-
valence, and excess mortality, as would be the case with 
chronic conditions. Instead, information is required on remis-
sion rates as well as recurrence rates, adding degrees of free-
dom which takes away the possibility of a unique set of 
parameters defining an internally consistent epidemiology. 
Calibration parameters were set to closely match available 
epidemiological evidence. The model’s resulting epidemiology 
was in line with the epidemiological evidence-base, with the 
exception of two of 13 recurrence rates, which were below the 
confidence interval as reported by Solomon et al. (2000); thus 
indicating that the risk of recurrence in DepMod is slightly 
lower in these instances, thereby resulting in conservative 
estimates of the cost-effectiveness of preventive interventions 
[32]. Final parameter choices were checked for face-validity 
with experts in the field of depression. Future research should 
aim to validate these findings.
Table 2. Illustration of selected evidence-based interventions by depression severity level: target group reached by the intervention expressed as Coverage (%) and 
Compliance with therapy (%). Effect expressed as risk difference (RD) or Relative Risk (RR) when impacting on transitions or as standardized effect size (Cohen’s d) 
when impacting on symptom severity, all representing average values.
Intervention by depression severity level Coverage rate Compliance rate Effect
Prevention of first incidence (targeting subclinical depression) % % RD
E-health intervention (unsupported) 1 0 80 0.077
Treatment of mild depression % % d
E-health intervention (supported) 2 2 43 0.33
Individual psychological intervention, primary care, 8 sessions 3 17 56 0.51
Treatment of moderate depression % % d
E-health intervention (supported) 2 2 43 0.33
Individual psychological intervention, primary care, 8 sessions 3 16 56 0.51
% % d
Individual psychological outpatient care, 8–24 sessions 3 18 68 0.51
Anti-depressants, 3–6 months via GP 4 20 44 0.30
Anti-depressants, 3–6 months, with psychological support 3 20 56 0.51
Prevention of recurrent depression % % RR
Clinical management with maintenance medication, 12 months 5 0 42 0.75
Mindfulness-based CT 6 0 68 0.66
Cognitive (behavior) therapy 6 0 56 0.68
1Taken from van Zoonen et al. 2014 [15]; 2 Taken from Karyotaki et al. 2017 [38]; 3 Taken from Cuijpers et al. 2019 [10]; 4 Taken from Cipriani et al. 2018 [39]; 5 Taken 
from Vittengl et al. 2007 [40]; 6 Taken from Biesheuvel-Leliefeld et al. 2015 [41]. 
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Fourth, we chose to model epidemiology using a Markov- 
model rather than a discrete event model. Both models have 
their strengths and limitations. As our aim was to make 
a population-level model, we were less interested in the ability 
of our model to capture individual traits affecting the course 
of illness. Nevertheless, cost-effectiveness might be affected 
by clinicians adjusting their treatment decisions based on the 
patient’s personal traits. We partly compensated for this by 
modeling two forms of heterogeneity in the epidemiology. 
First, the severity of depression (mild, moderate, and severe) 
Figure 5. (a) Cost-effectiveness plane (top) and (b) cost-effectiveness acceptability curve (bottom) associated with scaling up prevention. The cost-effectiveness 
acceptability curve expresses the probability that scaling up prevention is cost-effective (y-axis) and on the x-axis the willingness to pay for one QALY gained given 
various ceiling ratios.
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was captured in the model. Second, the number of previous 
episodes was accounted for in the model using tunnel states. 
By adding these features, patient heterogeneity was consid-
ered to a limited extent. Moreover, as nuances such as med-
ication switching were not specifically incorporated, ideally 
they should be captured within the parameters of each inter-
vention (e.g., included in the average costs and average effect 
size of pharmacotherapy).
Fifth, we used one-year cycles in the model as available 
epidemiological evidence did not provide enough information 
for a shorter cycle-length. This allowed only one transition or 
episode of depression per year, even though changes in the 
course of depression can occur more frequently.
Sixth, ideally all healthcare costs, not only in the mental 
healthcare services, would be used for each health state, as 
depression could be associated with additional healthcare 
usage in general. Moreover, one would ideally also have data 
on the care patients receive when in intermediate (remissions 
and recurrences) states. These types of costs, but also other 
types of costs such as productivity losses, are not covered in 
the model. Moreover, although the model is unable to track 
how many treatments each patient has received (i.e., given it 
is a population model) and in theory patients could receive 
the same treatment multiple times during the five-year time 
horizon (each time with the same assumed effectiveness), this 
is likely only an issue when users would implement a 100% 
coverage rate for a specific intervention. In addition, the 
model is not optimally suited for treatments with 
a treatment duration longer than the time horizon (i.e., 
1 year), given that treatments are offered every cycle.
Seventh, using NEMESIS-2 as our main source of epidemio-
logical input, DepMod is restricted to the population aged 
18–65 years. Using the model for other age-groups requires 
updating the input parameters to the setting and age group 
of interest.
Eighth, people in DepMod remain in their initial mild, mod-
erate, or severe depression severity level throughout the 
entire period under consideration, whereas in reality people 
could transition between severity levels. Also, our model is 
limited to major depressive disorder and does not consider 
dysthymia.
Ninth, DepMod reports on the desirability of an alternative 
setup of the healthcare system from a perspective of cost- 
effectiveness, but does not take into account other perspec-
tives, such as equity, feasibility, sustainability, and 
acceptability.
Tenth, QALYs were calculated based on disability weights 
instead of utility values based on Stouthard et al. (1997) and 
Sanderon et al.’s (2004) conversion factor. A disability 
weight is a weight factor that reflects the severity of the 
disease on a scale from 0 (perfect health) to 1 (equivalent to 
death). In contrast, a utility represents the quality of 
a health state on a scale from 0 (equivalent to death) to 1 
(perfect health). In general, a utility value incorporates 
a broader spectrum of dimensions of health state, not 
merely focusing on disease related factors and may also 
lead to states worse than death. However, the disability 
weights derived by Stouthard et al. (1997) were based on 
the EuroQol-5D instrument, an instrument commonly used 
to obtain utility values and therefore captures this broader 
view.
Last, DepMod constitutes a relatively short time horizon, in 
avoid extrapolating too far from the available epidemiological 
evidence-base. However, the implementation of a life time horizon 
may enable decision makers to more adequately capture societal 
costs, for example, it is known that depression is frequently asso-
ciated with low marital quality, low work performance, and low 
earnings, thereby increasing societal costs and decreasing quality 
of life [50]. The episodic nature of depression underscores the 
importance of identifying individuals at ultra-high risk of relapse 
or recurrence, as enduring depression symptoms may require 
further treatment and continue to generate personal, financial, 
and societal costs [51, 52]. Future research should therefore focus 
on developing a health-economic model using patient-level simu-
lations (e.g., a discrete-event simulation) to determine the impact 
of personalized preventive actions targeting patients at high risk 
of a recurrent depression.
5. Conclusion
Overall, our model estimates the cost-effectiveness of changing 
the configuration of a healthcare system for depression. 
Outcomes of the model should always be considered in light of 
other equally important (societal) values such as equity, feasibil-
ity, sustainability, and acceptability (see for example [52]). Above 
all, our model aims to facilitate decision-making with respect to 
optimizing the healthcare system for major depressive disorder 
but should never be seen as an auto-pilot for decision-making.
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Appendix 1
Tabulated results of real-world example
Total costs (95%CI) Total QALYs (95%CI) Incremental costs Incremental QALYs ICER
Reference scenario €632,198 (€566,008 – €700,627) 36,662 (27,079–48,500) NA NA NA
Alternative scenario €823,304 (€748,926 – €898,681) (55,069 (42,569–71,031) €191,106 18,408 €10 per QALY gained
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